Influenza virus hemagglutinin stalk-based antibodies and vaccines.
Florian Krammer,Peter Palese +1 more
Reads0
Chats0
TLDR
Broadly protective vaccine candidates based on the epitopes of these antibodies, for example, chimeric and headless hemagglutinin structures, are under development and show promising results in animals models, and could be developed into universal influenza virus vaccines that protect from infection with drifted seasonal as well as novel pandemic influenza virus strains therefore obviating the need for annual vaccination, and enhancing pandemic preparedness.About:
This article is published in Current Opinion in Virology.The article was published on 2013-10-01 and is currently open access. It has received 301 citations till now. The article focuses on the topics: Influenza A virus & H5N1 genetic structure.read more
Citations
More filters
Journal ArticleDOI
A potent anti-influenza compound blocks fusion through stabilization of the prefusion conformation of the hemagglutinin protein
Kris M. White,Paul D. De Jesus,Zhong Chen,Pablo Abreu,Elisa Barile,Puiying A. Mak,Paul Anderson,Quy T. Nguyen,Atsushi Inoue,Silke Stertz,Renate Koenig,Maurizio Pellecchia,Peter Palese,Kelli Kuhen,Adolfo García-Sastre,Sumit K. Chanda,Megan L. Shaw +16 more
TL;DR: Mechanism of action studies proved a direct S20–HA interaction and showed that S20 inhibits fusion by stabilizing the prefusion conformation of HA, which shows potent antiviral activity and low toxicity.
Journal ArticleDOI
Recombinant hemagglutinin influenza vaccine provides broader spectrum protection
Lisa M. Dunkle,Ruvim Izikson +1 more
TL;DR: These data suggest that the rHA proteins produced in Lepidopteran cells offer broader-spectrum protection and result in clinical benefit, and may be achieved with immunity directed at more conserved viral antigens.
Journal ArticleDOI
Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
Rory D. de Vries,Arwen F. Altenburg,Nella J. Nieuwkoop,Erwin de Bruin,Stella E. van Trierum,Mark Pronk,Mart M. Lamers,Mathilde Richard,David F. Nieuwenhuijse,Marion Koopmans,Joost H. C. M. Kreijtz,Ron A. M. Fouchier,Albert D. M. E. Osterhaus,Gerd Sutter,Guus F. Rimmelzwaan +14 more
TL;DR: These findings validate rMVA-H5 as vaccine candidate against antigenically distinct H5 viruses, including the recently emerged subtypes H5N6 and H5n8 and the currently circulating subtype H 5N1.
Journal ArticleDOI
Sustainable vaccine development: a vaccine manufacturer's perspective
Rino Rappuoli,Emmanuel Hanon +1 more
TL;DR: This work states that vaccine development can be fast-tracked through strengthening international collaborations, and the continuous innovation of technologies to accelerate their design, development, and manufacturing, but these processes should be supported by a balanced project portfolio, and by managing sustainable vaccine procurement strategies for different types of markets.
Posted ContentDOI
Accurate measurement of the effects of all amino-acid mutations to influenza hemagglutinin
Michael B. Doud,Jesse D. Bloom +1 more
TL;DR: The authors' measurements confirm that antigenic sites on the globular head of hemagglutinin are highly tolerant of mutations, but other regions – including stalk epitopes targeted by broadly neutralizing antibodies – have a limited capacity to evolve.
References
More filters
Journal ArticleDOI
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
Rongbao Gao,Bin Cao,Yunwen Hu,Zijian Feng,Dayan Wang,Wanfu Hu,Jian Chen,Zhijun Jie,Haibo Qiu,Ke Xu,Xuewei Xu,Hongzhou Lu,Wenfei Zhu,Zhancheng Gao,Nijuan Xiang,Yinzhong Shen,Zebao He,Y. Gu,Zhiyong Zhang,Yi Yang,Xiang Zhao,Lei Zhou,Xiaodan Li,Shumei Zou,Ye Zhang,Xiyan Li,Lei Yang,Junfeng Guo,Jie Dong,Qun Li,Libo Dong,Yun Zhu,Tian Bai,Shiwen Wang,Pei Hao,Weizhong Yang,Yanping Zhang,Jun Han,Hongjie Yu,Dexin Li,George F. Gao,Guizhen Wu,Yu Wang,Zhenghong Yuan,Yuelong Shu +44 more
TL;DR: Novel reassortant H7N9 viruses were associated with severe and fatal respiratory disease in three patients, and all three patients died.
Journal ArticleDOI
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Damian C. Ekiert,Gira Bhabha,Marc-André Elsliger,Robert H. E. Friesen,Mandy Jongeneelen,Mark Throsby,Jaap Goudsmit,Ian A. Wilson +7 more
TL;DR: TheCR6261 epitope identified here should accelerate the design and implementation of improved vaccines that can elicit CR6261-like antibodies, as well as antibody-based therapies for the treatment of influenza.
Journal ArticleDOI
Structural and Functional Bases for Broad-Spectrum Neutralization of Avian and Human Influenza A Viruses
Jianhua Sui,William C. Hwang,Sandra Elizabeth Pérez,Ge Wei,Daniel Aird,Li-Mei Chen,Eugenio Santelli,Boguslaw Stec,Greg Cadwell,Maryam Ali,Hongquan Wan,Akikazu Murakami,Anuradha Yammanuru,Thomas Han,Nancy J. Cox,Laurie A. Bankston,Ruben O. Donis,Robert C. Liddington,Wayne A. Marasco +18 more
TL;DR: The crystal structure of one such nAb bound to H5 shows that it blocks infection by inserting its heavy chain into a conserved pocket in the stem region, thus preventing membrane fusion, and suggests that nAb-based immunotherapy is a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.
Journal ArticleDOI
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins
Davide Corti,Jarrod Voss,Steven J. Gamblin,Giosiana Codoni,Annalisa Macagno,David Jarrossay,Sebastien G. Vachieri,Debora Pinna,Andrea Minola,Fabrizia Vanzetta,Chiara Silacci,Blanca Fernandez-Rodriguez,Gloria Agatic,Siro Bianchi,Isabella Giacchetto-Sasselli,Lesley J. Calder,Federica Sallusto,Patrick J. Collins,Lesley F. Haire,Nigel J. Temperton,Johannes P. M. Langedijk,John J. Skehel,Antonio Lanzavecchia +22 more
TL;DR: An antibody able to broadly neutralize both group 1 and group 2 influenza A viruses—and its target epitope—are identified and may be used for passive protection and to inform vaccine design because of its broad specificity and neutralization potency.
Journal ArticleDOI
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
Jens Wrammert,Kenneth J. Smith,Joseph I. Miller,William A. Langley,Kenneth E. Kokko,Christian P. Larsen,Nai-Ying Zheng,Israel Mays,Lori Garman,Christina Helms,Judith A. James,Judith A. James,Gillian M. Air,J. Donald Capra,J. Donald Capra,Rafi Ahmed,Patrick C. Wilson,Patrick C. Wilson +17 more
TL;DR: The panel of influenza-virus-specific human mAbs allowed us to address the issue of original antigenic sin (OAS): the phenomenon where the induced antibody shows higher affinity to a previously encountered influenza virus strain compared with the virus strain present in the vaccine.
Related Papers (5)
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins
Davide Corti,Jarrod Voss,Steven J. Gamblin,Giosiana Codoni,Annalisa Macagno,David Jarrossay,Sebastien G. Vachieri,Debora Pinna,Andrea Minola,Fabrizia Vanzetta,Chiara Silacci,Blanca Fernandez-Rodriguez,Gloria Agatic,Siro Bianchi,Isabella Giacchetto-Sasselli,Lesley J. Calder,Federica Sallusto,Patrick J. Collins,Lesley F. Haire,Nigel J. Temperton,Johannes P. M. Langedijk,John J. Skehel,Antonio Lanzavecchia +22 more